J&J says Jardiance survival benefit likely to be seen by Invokana
October 13, 2015 at 10:29 AM EDT
Oct 13 (Reuters) - Johnson & Johnson said on Tuesday that the ability of Eli Lilly and Co's rival Jardiance diabetes drug to save lives in a large clinical trial is likely to benefit the entire class of drugs, including J&J's own approved Invokana treatment.
